Survodutide vs Semaglutide
A dual glucagon and GLP-1 receptor agonist — the co-agonist that skips GIP and aims at the liver. A long-acting GLP-1 receptor agonist engineered for once-weekly dosing. Side by side: type, evidence tier, receptor, molecular weight, and half-life — the same fields as each monograph, rearranged so the engineering difference is visible.
Survodutide BI 456906 | Semaglutide | |
|---|---|---|
| Also known as | — | Ozempic, Wegovy, Rybelsus |
| Type | Analog | Analog |
| Evidence | Investigational | Established |
| Family | Incretins & metabolic | Incretins & metabolic |
| Class | Glucagon/GLP-1 dual receptor agonist (acylated peptide) | GLP-1 receptor agonist (acylated peptide, 31 aa) |
| Receptor / target | Glucagon receptor (GCGR) + GLP-1 receptor | GLP-1 receptor (GLP-1R) |
| Molecular weight | ≈4,800 Da | ~4,113.6 Da |
| Half-life | engineered for once-weekly dosing | |
| Based on | Glucagon-like peptide-1 | Glucagon-like peptide-1 |
Half-life bars are on a logarithmic scale across the molecules shown. Reference values for the native or representative form — educational only, not medical or dosing advice.
Common questions
- What is the difference between Survodutide and Semaglutide?
- Survodutide is an engineered analog based on Glucagon-like peptide-1; Semaglutide is an engineered analog based on Glucagon-like peptide-1. Survodutide signals at Glucagon receptor (GCGR) + GLP-1 receptor; Semaglutide signals at GLP-1 receptor (GLP-1R).
- How do the half-lives of BI 456906 and Semaglutide compare?
- The reported circulating half-life of Survodutide is engineered for once-weekly dosing; Semaglutide is ~7 days (~165 h). These are reference values for the native or representative form — educational only, not dosing advice.
Prefer the other order? Semaglutide vs Survodutide. Or open the interactive comparison tool to add more molecules.